Ying Qu1, Lei Zong1, Mingyi Xu1, Yuwei Dong1, Lungen Lu1. 1. Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine Shanghai 200080, China.
Abstract
BACKGROUND: Glycyrrhizin has various pharmacological effects including hepato-protection. This study aimed to investigate the potential mechanism underlying the protective effects of 18α-glycyrrhizin (18α-GL) in rats with carbon tetrachloride (CCl4) induced liver fibrosis. METHODS: Male Sprague-Dawley (SD) rats were randomly divided into control group, fibrosis group, 25 mg/kg 18α-GL group and 12.5 mg/kg 18α-GL group. Rats in experimental groups were subcutaneously injected with 40% CCl4 twice weekly for 8 weeks. Immunohistochemical examination was carried out to detect the protein expressions of collagen I, collagen III, TGF-β1, p-Smad2, p-Smad3, Smad 7 and SP-1, in the liver, and the mRNA and protein expressions of these genes were determined in the liver by real time PCR and Western blot assay, respectively. RESULTS: 18α-GL ameliorated histological changes and significantly suppressed collagen deposition. 18α-GL significantly decreased the mRNA expressions of TGF-β1, Smad2, Smad3 and SP-1 in the liver. Immunohistochemical staining revealed that TGF-β1, p-Smad2, p-Smad3 and SP-1 expressions reduced following 18α-GL therapy. Western blot assay showed p-Smad2, p-Smad3, smad2 and smad3 expressions decreased after 18α-GL treatment. The mRNA and protein expression of Smad7 remained unchanged. CONCLUSION: 18α-GL is able to attenuate CCl4 induced liver fibrosis in rat.
BACKGROUND: Glycyrrhizin has various pharmacological effects including hepato-protection. This study aimed to investigate the potential mechanism underlying the protective effects of 18α-glycyrrhizin (18α-GL) in rats with carbon tetrachloride (CCl4) induced liver fibrosis. METHODS: Male Sprague-Dawley (SD) rats were randomly divided into control group, fibrosis group, 25 mg/kg 18α-GL group and 12.5 mg/kg 18α-GL group. Rats in experimental groups were subcutaneously injected with 40% CCl4 twice weekly for 8 weeks. Immunohistochemical examination was carried out to detect the protein expressions of collagen I, collagen III, TGF-β1, p-Smad2, p-Smad3, Smad 7 and SP-1, in the liver, and the mRNA and protein expressions of these genes were determined in the liver by real time PCR and Western blot assay, respectively. RESULTS: 18α-GL ameliorated histological changes and significantly suppressed collagen deposition. 18α-GL significantly decreased the mRNA expressions of TGF-β1, Smad2, Smad3 and SP-1 in the liver. Immunohistochemical staining revealed that TGF-β1, p-Smad2, p-Smad3 and SP-1 expressions reduced following 18α-GL therapy. Western blot assay showed p-Smad2, p-Smad3, smad2 and smad3 expressions decreased after 18α-GL treatment. The mRNA and protein expression of Smad7 remained unchanged. CONCLUSION: 18α-GL is able to attenuate CCl4 induced liver fibrosis in rat.
Authors: Masayuki Uemura; E Scott Swenson; Marianna D A Gaça; Frank J Giordano; Michael Reiss; Rebecca G Wells Journal: Mol Biol Cell Date: 2005-06-29 Impact factor: 4.138
Authors: H Sato; W Goto; J Yamamura; M Kurokawa; S Kageyama; T Takahara; A Watanabe; K Shiraki Journal: Antiviral Res Date: 1996-05 Impact factor: 5.970
Authors: Ashraf U Nissar; Mufti R Farrukh; Peerzada J Kaiser; Rather A Rafiq; Quadri Afnan; Shashi Bhushan; Hassan S Adil; Bhardjwaj C Subhash; Sheikh A Tasduq Journal: Phytomedicine Date: 2013-04-09 Impact factor: 5.340